Aptevo Therapeutics EPS - Earnings per Share 2014-2022 | APVO

Aptevo Therapeutics eps - earnings per share from 2014 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Aptevo Therapeutics Annual EPS
2021 $-6.07
2020 $-5.23
2019 $-13.86
2018 $-33.47
2017 $4.62
2016 $-77.73
2015 $-41.04
2014 $0.00
2013 $0.00
Aptevo Therapeutics Quarterly EPS
2022-03-31 $-1.55
2021-12-31 $-1.25
2021-09-30 $-1.43
2021-06-30 $-1.75
2021-03-31 $-1.64
2020-12-31 $-1.92
2020-09-30 $-2.10
2020-06-30 $-2.10
2020-03-31 $0.89
2019-12-31 $0.07
2019-09-30 $-2.15
2019-06-30 $-4.14
2019-03-31 $-7.64
2018-12-31 $-8.82
2018-09-30 $-7.70
2018-06-30 $-8.12
2018-03-31 $-8.82
2017-12-31 $-5.74
2017-09-30 $24.51
2017-06-30 $-7.42
2017-03-31 $-6.72
2016-12-31 $-10.22
2016-09-30 $-49.72
2016-06-30 $-8.82
2016-03-31 $-8.96
2015-12-31 $0.00
2015-09-30 $-8.82
2015-06-30 $-12.33
2014-12-31 $0.00
2013-12-31 $0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.022B $0.012B
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $159.845B 9.70
GSK (GSK) United Kingdom $77.890B 9.35
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.320B 18.95
Biohaven Pharmaceutical Holding (BHVN) United States $10.518B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.561B 0.00
Arcus Biosciences (RCUS) United States $1.948B 38.03
Myovant Sciences (MYOV) United Kingdom $1.688B 0.00
Emergent Biosolutions (EBS) United States $1.521B 8.81
Zymeworks (ZYME) Canada $0.397B 0.00
Enzo Biochem (ENZ) United States $0.127B 0.00
Gelesis Holdings (GLS) United States $0.099B 0.00
SQZ Biotechnologies (SQZ) United States $0.098B 0.00
Ambrx Biopharma (AMAM) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00